Payment overview · 2025
General Payments
$130.96
6 reported records · 4 companies
Healthcare provider profile · identity verified
Edgar A Figueroa, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · DEER PARK, WA · NPI 1487650883
Verified facts
What the public records show
CMS Open Payments records show Edgar A Figueroa, M.D. received $130.96 in general payments during 2025 across 6 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 35.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rybelsus.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 309 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synjardy by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $46.80 | 35.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $44.15 | 33.7% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.81 | 16.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.20 | 13.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $130.96 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $46.80 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $21.81 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.62 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.62 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.20 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 309 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 177 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
309 | 57 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
177 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
63 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 560 | 68 |
| Atorvastatin Calcium | Atorvastatin Calcium | 534 | 122 |
| Lisinopril | Lisinopril | 320 | 72 |
| Levothyroxine Sodium | Levothyroxine Sodium | 313 | 66 |
| Jardiance | Empagliflozin | 309 | 57 |
| Gabapentin | Gabapentin | 301 | 63 |
| Amlodipine Besylate | Amlodipine Besylate | 222 | 50 |
| Losartan Potassium | Losartan Potassium | 205 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 201 | 51 |
| Ozempic | Semaglutide | 177 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 177 | 37 |
| Omeprazole | Omeprazole | 170 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 166 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 166 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 160 | 42 |
| Furosemide | Furosemide | 160 | 23 |
| Trazodone Hcl | Trazodone Hcl | 155 | 25 |
| Potassium Chloride | Potassium Chloride | 154 | 28 |
| Bupropion Xl | Bupropion Hcl | 151 | 23 |
| Warfarin Sodium | Warfarin Sodium | 130 | 16 |
| Metformin Hcl Er | Metformin Hcl | 127 | 27 |
| Metformin Hcl | Metformin Hcl | 124 | 33 |
| Pregabalin | Pregabalin | 120 | 25 |
| Sertraline Hcl | Sertraline Hcl | 117 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 114 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 107 | 24 |
| Oxycodone Hcl | Oxycodone Hcl | 105 | 15 |
| Glipizide Er | Glipizide | 100 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 99 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 99 | 15 |
| Mirtazapine | Mirtazapine | 96 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 92 | 19 |
| Prednisone | Prednisone | 92 | 40 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 87 | 13 |
| Ezetimibe | Ezetimibe | 86 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 85 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 83 | 19 |
| Alendronate Sodium | Alendronate Sodium | 81 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 74 | 12 |
| Spironolactone | Spironolactone | 73 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 69 | 24 |
| Memantine Hcl | Memantine Hcl | 66 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 65 | 11 |
| Eliquis | Apixaban | 63 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 63 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 62 | suppressed |
| Allopurinol | Allopurinol | 56 | 15 |
| Vascepa | Icosapent Ethyl | 55 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 52 | 11 |
| Entresto | Sacubitril/Valsartan | 51 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 50 | 11 |
| Clonidine Hcl | Clonidine Hcl | 50 | suppressed |
| Atenolol | Atenolol | 49 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 48 | 11 |
| Xarelto | Rivaroxaban | 48 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 47 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 47 | 15 |
| Baclofen | Baclofen | 46 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 46 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | 14 |
| Aripiprazole | Aripiprazole | 43 | suppressed |
| Meloxicam | Meloxicam | 43 | suppressed |
| Carvedilol | Carvedilol | 42 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 42 | suppressed |
| Famotidine | Famotidine | 40 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 38 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | suppressed |
| Topiramate | Topiramate | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 37 | suppressed |
| Estradiol | Estradiol | 37 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | suppressed |
| Trulicity | Dulaglutide | 36 | suppressed |
| Finasteride | Finasteride | 35 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | suppressed |
| Methocarbamol | Methocarbamol | 34 | 12 |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 34 | suppressed |
| Torsemide | Torsemide | 34 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 30 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Rybelsus | Semaglutide | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Simvastatin | Simvastatin | 29 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 28 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 19 |
| Indapamide | Indapamide | 26 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Oxycontin | Oxycodone Hcl | 25 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 24 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 24 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Risperidone | Risperidone | 24 | suppressed |
| Alprazolam | Alprazolam | 23 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 22 |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 17 |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 21 | 15 |
| Latanoprost | Latanoprost | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 11 |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 13 | suppressed |
| Etodolac | Etodolac | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | suppressed |
| Budesonide Ec | Budesonide | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Cymbalta | Duloxetine Hcl | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Progesterone | Progesterone, Micronized | 12 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 11 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 11 | suppressed |
| Humulin R | Insulin Regular, Human | 11 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $130.96 · 6 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA, JARDIANCE, NURTEC ODT, Ozempic, Rybelsus, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error